Loading
NYSEReal EstateReal Estate - Services
Latest quote
$1.49
+$0.01 · +0.68%
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Regular session
$1.49
+$0.01 · +0.68%
Regular session · ET · Market data may be delayed.
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Day range
Current $1.49
52-week range
Current $1.49
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
53
Fair Value
Sentiment
60
Mixed
Risk
62
High Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Day range
Current $1.49
52-week range
Current $1.49
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 917K USD | 637K USD | 279K USD | 410K USD | 802K USD |
| Cost of goods sold | 422K USD | 154K USD | — | — | 70K USD |
| Gross profit | 495K USD | 483K USD | 279K USD | 410K USD | 802K USD |
| Research and development | 12.82M USD | 94.03M USD | 6.31M USD | 8.74M USD | 4.91M USD |
| Selling, general, and administrative | 13.78M USD | 8.85M USD | 8.93M USD | 16.98M USD | 20.42M USD |
| Operating expenses | 26.6M USD | 103.11M USD | 15.32M USD | 60.89M USD | 29M USD |
| Interest income | 2M USD | 2.38M USD | 3.25M USD | 201K USD | 2K USD |
| Interest expense | 658K USD | 248K USD | — | 6K USD | 12K USD |
| Depreciation and amortization | 288K USD | 225K USD | 78K USD | 72K USD | 70K USD |
| Operating income | −26.11M USD | −102.63M USD | −15.04M USD | −60.48M USD | −21.2M USD |
| Net income | −30.52M USD | −34.41M USD | −1.88M USD | −124.66M USD | −24.54M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Dec 18, 2009 | $0.02Semi-Annual | — | Dec 31, 2009 |
Dividend | Jun 19, 2009 | $0.02Semi-Annual | — | Jun 30, 2009 |
Ex-dividend Dec 18, 2009
$0.02
Semi-Annual
Payment Dec 31, 2009
Ex-dividend Jun 19, 2009
$0.02
Semi-Annual
Payment Jun 30, 2009
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.51M0.00%2.3T USD0.03%$379.37-0.44%
Vanguard Extended Market ETFVXF1.22M0.00%95.4B USD0.05%$231.9-0.68%
iShares Micro-Cap ETFIWC154.67K0.01%1.33B USD0.60%$181.41-1.07%
U.S. Micro Cap Portfolio ETFDFMC138.14K0.00%7.52B USD0.43%$57.42-0.14%
Dimensional - US Small Cap ETFDFAS66.71K0.00%33.66B USD0.31%$77.665-0.33%
Dimensional - US Core Equity 2 ETFDFAC54.3K0.00%88.28B USD0.21%$45.025-0.34%
U.S. Vector Equity Portfolio ETF Class SharesDXUV35.7K0.00%6.16B USD0.26%$67.91-0.07%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR29.35K0.00%45.43B USD0.17%$83.825-0.33%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASDimensional - US Core Equity 2 ETFDFACU.S. Vector Equity Portfolio ETF Class SharesDXUVU.S. Core Equity 1 Portfolio ETF Class SharesDCORAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
